Advertisement
Screener

INNOVIVA, INC. (INVA) Graph

INVA Revenue Flow

Filed revenue amounts for 2026-04-01 to 2026-06-30. Coverage is partial. Unconnected amounts are separate disclosures; they must not be added together.

  • 2026-06-30: Revenue $119.59M; Research and development $5.19M; Selling, general and administrative $34.57M; Operating expenses $39.76M.
  • 2026-03-31: Revenue $97.99M; Research and development $5.24M; Selling, general and administrative $32.44M; Operating expenses $37.68M.
  • 2025-12-31: Revenue $114.61M*; Research and development $4.55M*; Selling, general and administrative $32.12M*; Operating expenses $36.68M*.
  • 2025-09-30: Revenue $107.80M; Research and development $13.67M; Selling, general and administrative $27.29M; Operating expenses $40.96M.

Consolidation item

Separate filed amounts; connecting flows are not established. Components and totals may overlap.

INVA revenue flowFiled amounts. Only explicit calculation relationships connect amounts; dimensional membership alone does not establish an additive flow.Operating Segments$119.59MRevenue$119.59MGross profit$90.62MOperating expenses$39.76MOperating income$50.86MOther income, net-$15.00KResearch & development$5.19MSelling, general& administrative$34.57MPre-tax income-$108.02MIncome tax-$24.60MNet income-$83.42M

Product or service

Separate filed amounts; connecting flows are not established. Components and totals may overlap.

INVA revenue flowFiled amounts. Only explicit calculation relationships connect amounts; dimensional membership alone does not establish an additive flow.Product$51.77MRoyalty$56.33MGiapreza$22.30MLicense AndOther Revenue$11.49MXacduro$22.38MXerava$6.74MZEVTERA$351.00KRevenue$119.59MGross profit$90.62MOperating expenses$39.76MOperating income$50.86MOther income, net-$15.00KResearch & development$5.19MSelling, general& administrative$34.57MPre-tax income-$108.02MIncome tax-$24.60MNet income-$83.42M

Finer product or service dollar figures and nonoverlapping groupings are shown only where supported by the retained filing evidence. Growth percentages are never converted to revenue dollars.

Historical revenue and expense breakdown

Revenue and expense 3 month

Period endRevenueResearch and developmentSelling, general and administrativeOperating expensesIncome taxNet income
2026-06-30$119.59M$5.19M$34.57M$39.76M-$24.60M(m)
2026-03-31$97.99M$5.24M$32.44M$37.68M$47.97M(m)
2025-12-31$114.61M*$4.55M*$32.12M*$36.68M*$30.88M*(m)
2025-09-30$107.80M$13.67M$27.29M$40.96M$7.91M(m)
2025-06-30$100.28M$7.98M$26.41M$34.40M$8.91M(m)
2025-03-31$88.63M$4.40M$27.49M$31.89M$8.00M(m)
2024-09-30$89.51M$3.55M$26.22M$29.77M$5.64M(m)
2024-06-30$99.90M$2.56M$27.74M$30.30M-$4.59M(m)
2024-03-31$77.50M$3.88M$30.41M$34.28M$8.59M(m)
2023-09-30$67.26M$3.99M$28.64M(m)$3.91M(m)
2023-06-30$80.99M$14.99M$23.54M(m)$4.53M(m)
2023-03-31$76.37M$12.59M$19.73M(m)$6.28M(m)
2022-09-30$67.26M$11.72M$27.81M-$219.17M$57.08M(m)
2022-06-30$108.22M$13.88M$11.78M$25.67M-$876.00K(m)
2022-03-31$90.06M$5.84M$6.49M$12.33M$6.86M(m)
2021-09-30$97.86M$449.00K$2.86M-$25.32M$20.53M(m)
2021-06-30$100.81M$38.00K(m)$4.27M$25.33M(m)
2021-03-31$85.52M$49.00K(m)$6.04M$19.74M(m)
2020-09-30$88.69M$1.01M(m)$4.26M$8.87M(m)
2020-06-30$78.95M$559.00K(m)$3.15M$19.89M(m)
2020-03-31$78.68M$0.00(m)$2.56M$15.93M(m)
2019-12-31$75.97M(m)(m)$2.33M$12.40M(m)
2019-09-30$65.75M$0.00(m)$4.96M$10.56M(m)
2019-06-30$64.11M$0.00(m)$4.35M$10.43M(m)
2019-03-31$55.18M(m)(m)$3.02M$8.51M(m)
2018-12-31$79.86M(m)(m)$2.64M-$196.07M(m)
2018-09-30$61.68M$0.00(m)$4.02M$0.00(m)
2018-06-30$67.09M$0.00(m)$4.41M$0.00(m)
2018-03-31$52.38M$0.00(m)$11.69M$0.00(m)
2017-12-31$69.52M(m)(m)$3.11M$4.00K(m)
2017-09-30$48.64M$311.00K(m)$8.62M$0.00(m)
2017-06-30$58.56M$348.00K(m)$10.73M$0.00(m)
2017-03-31$40.49M$354.00K(m)$11.15M$0.00(m)
2016-12-31$43.61M(m)(m)$5.95M(m)(m)
2016-09-30$33.31M$286.00K(m)$5.39M(m)(m)
2016-06-30$32.47M$370.00K(m)$6.59M(m)(m)
2016-03-31$24.18M$392.00K(m)$6.64M(m)$4.43M
2015-12-31$22.84M(m)(m)$5.54M(m)(m)
2015-09-30$13.56M$547.00K(m)$5.13M$0.00(m)
2015-06-30$10.65M$638.00K(m)$5.55M$0.00(m)
2015-03-31$6.90M$712.00K(m)$6.15M(m)-$10.67M
2014-12-31$7.28M(m)(m)$7.15M(m)(m)
2014-09-30$999.00K$1.91M(m)$10.54M-$278.00K(m)
2014-06-30$934.00K$2.13M(m)$10.73M$278.00K(m)
2014-03-31-$780.00K$2.69M$22.83M$13.94M(m)(m)
2013-12-31$1.47M(m)$16.47M*$8.89M(m)(m)
2013-09-30$415.00K$2.10M$12.28M$8.12M$0.00(m)
2013-06-30$1.32M$2.41M(m)$8.22M$0.00(m)
2013-03-31$1.32M$26.42M$8.31M$8.10M(m)(m)
2012-09-30$1.43M$27.03M$7.75M$34.78M(m)(m)
2012-06-30$1.43M$29.55M(m)$37.14M(m)(m)
2012-03-31$127.10M$33.20M(m)$41.06M(m)$84.59M
2011-09-30$6.43M$27.84M(m)$35.63M(m)(m)
2011-06-30$6.39M$22.80M(m)$30.05M(m)(m)
2011-03-31$6.33M$20.46M(m)$27.63M(m)-$22.67M
2010-09-30(m)$18.54M(m)$25.15M(m)(m)
2010-06-30(m)$18.70M(m)$25.70M(m)(m)

Revenue and expense 6 month

Period endRevenueResearch and developmentSelling, general and administrativeOperating expensesIncome tax
2026-06-30$217.59M$10.43M$67.01M$77.44M$23.37M
2025-06-30$188.91M$12.38M$53.90M$66.28M$16.91M
2024-06-30$177.40M$6.44M$58.15M$64.58M$4.00M
2023-06-30$157.36M$27.58M$43.28M(m)$10.80M
2022-06-30$198.28M$19.72M$18.27M$38.00M$5.98M
2021-06-30$186.32M$87.00K(m)$10.30M$45.07M
2020-06-30$157.62M$559.00K(m)$5.72M$35.82M
2019-06-30$119.29M$0.00(m)$7.36M$18.94M
2018-06-30$119.47M$0.00(m)$16.10M$0.00
2017-06-30$99.05M$702.00K(m)$21.88M(m)
2016-06-30$56.65M$762.00K(m)$13.24M(m)
2015-06-30$17.55M$1.35M(m)$11.70M$0.00
2014-06-30$154.00K$4.81M(m)$24.67M$278.00K
2013-06-30$2.64M$4.45M(m)$16.32M$0.00
2012-06-30$128.53M$62.75M(m)$78.20M(m)
2011-06-30$12.72M$43.26M(m)$57.68M(m)
2010-06-30(m)$39.06M(m)$52.52M(m)

Revenue and expense 9 month

Period endRevenueResearch and developmentSelling, general and administrativeOperating expensesIncome tax
2025-09-30$296.71M$26.05M$81.19M$107.24M$24.81M
2024-09-30$266.90M$9.99M$84.36M$94.35M$9.63M
2023-09-30$224.62M$31.57M$71.91M(m)$14.71M
2022-09-30$265.54M$31.45M$46.08M-$86.10M$63.06M
2021-09-30$284.19M$536.00K$13.07M-$104.60M$65.60M
2020-09-30$246.32M$1.57M(m)$9.98M$44.69M
2019-09-30$185.04M$0.00(m)$12.32M$29.50M
2018-09-30$181.15M$0.00(m)$20.11M$0.00
2017-09-30$147.70M$1.01M(m)$30.50M(m)
2016-09-30$89.96M$1.05M(m)$18.63M(m)
2015-09-30$31.11M$1.90M(m)$16.83M$0.00
2014-09-30$1.15M$6.72M(m)$35.21M$0.00
2013-09-30$3.06M$6.55M$31.97M$24.44M$0.00
2012-09-30$129.96M$89.78M$23.20M$112.98M(m)
2011-09-30$19.15M$71.10M(m)$93.31M(m)
2010-09-30(m)$57.59M(m)$77.67M(m)

Revenue and expense 12 month

Period endRevenueResearch and developmentSelling, general and administrativeOperating expensesIncome tax
2025-12-31$411.33M$30.60M$113.32M$143.92M$55.70M
2024-12-31$358.71M$13.65M$115.69M$129.34M$14.00M
2023-12-31$310.46M$33.92M$98.23M$132.15M$14.38M
2022-12-31$331.34M$41.43M$63.54M(m)$66.69M
2021-12-31$391.87M$576.00K$16.19M$16.76M$76.44M
2020-12-31$336.79M$1.79M$13.88M$15.67M$60.43M
2019-12-31$261.02M$0.00(m)$14.66M$41.90M
2018-12-31$261.00M$0.00(m)$22.75M-$196.07M
2017-12-31$217.22M$1.35M(m)$33.61M$4.00K
2016-12-31$133.57M$1.39M(m)$24.58M$95.00K
2015-12-31$53.95M$2.62M(m)$22.37M$0.00
2014-12-31$8.43M$7.50M(m)$42.36M$0.00
2013-12-31$4.53M$9.04M$48.44M$33.33M$0.00
2012-12-31$5.61M$8.15M$30.86M$30.76M$0.00
2011-12-31$24.51M$103.57M$30.68M$134.25M$0.00
2010-12-31$24.22M$75.07M(m)$102.55M(m)
2009-12-31$24.37M$77.52M(m)$105.73M(m)

Similar stocks

Stock NameCountryMarket CapPE Ratio
ArriVent BioPharma, Inc. (AVBP)United States$1.485B-10.25
Ultragenyx Pharmaceutical Inc. (RARE)United States$1.456B-5.62
OMEROS CORP (OMER)United States$1.456B5.50
ANAPTYSBIO, INC (ANAB)United States$1.546B-60.20
Kailera Therapeutics, Inc. (KLRA)United States$1.552B
Syndax Pharmaceuticals Inc (SNDX)United States$1.606B-8.82
Oric Pharmaceuticals, Inc. (ORIC)United States$1.367B-8.00
Rapport Therapeutics, Inc. (RAPP)United States$1.623B-14.56
Stoke Therapeutics, Inc. (STOK)United States$1.630B-9.82
Xeris Biopharma Holdings, Inc. (XERS)United States$1.632B-80.10